Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Earlier this year, the NEJM published interim data on atacicept and sibeprenlimab in IgAN, both well-designed Phase 3 pivotal registration trials of promising drugs [1],[2]. Sponsors were clearly anxious to show the world how well their drug is working, but why publish interim results? After all, IA data are usually Continue reading IgAN Therapy – It’s Getting Crowded Out There
A recent Nature Review Drug Discovery article caught our attention, a review of TIGIT as an IO target and the failed Phase 3 study of tiragolumab which is the TIGIT inhibitor from Roche.[1] The science writer interviewed a group of insiders that had a lead role in the development of Continue reading The Tiragolumab Saga & Tifacogin Flash-Backs
Is there a new trend in the journal world: publication of interim analysis (IA) results? The NEJM recently published two articles back to back, both highlighting 9 month ‘interim’ data from Phase 3 pivotal trials in IgAN. The primary efficacy endpoint used in either study was UPCR at 9 months, Continue reading IgAN Therapeutics – The Race is On